PDF(Pubmed)
Abstract：
UNASSIGNED: IL-17A and IL-17F cytokines have important roles in the pathogenesis of psoriasis.
UNASSIGNED: To examine the associations of IL-17A rs2275913 and IL-17F rs763780 variants with the development of psoriasis and whether these polymorphisms affect the responsiveness of biological agents.
UNASSIGNED: In our case-controlled study, which included 83 psoriatic patients who were treated with different biological agents and 69 healthy controls, we genotyped IL-17A rs2275913 and IL-17F rs763780 variants using TaqMan probes.
UNASSIGNED: We did not observe statistically significant changes in genotype frequencies of IL-17A rs2275913 (p = 0.922) and IL-17F rs763780 (p = 0.621) variants between patient and control groups. Although we did not find any association between these polymorphisms and the development of psoriasis, statistical analyses showed that individuals with the IL-17A AA genotype had shorter disease duration (9.09 ±6.82, p = 0.020) and AA genotype frequency was higher in patients who used single conventional treatment (34.6%; p = 0.025). IL17A/rs2275913 variant in terms of disease duration, it was observed that individuals with AA genotype had a shorter disease duration (less than 10 years) (p = 0.009). For patients with PASI90 and PASI100 response, the IL-17A AA genotype was significantly higher (p = 0.015). On the other hand, we did not detect any statistically significant correlation between variants and response to biological agents.
UNASSIGNED: According to our results, we may suggest that rs2275913 variant seems to be associated with disease duration, use of single conventional treatment and responsiveness of PASI90 and PASI100 however both variants have no effect on the susceptibility to psoriasis in the population of Eastern Turkey.
UNASSIGNED: To examine the associations of IL-17A rs2275913 and IL-17F rs763780 variants with the development of psoriasis and whether these polymorphisms affect the responsiveness of biological agents.
UNASSIGNED: In our case-controlled study, which included 83 psoriatic patients who were treated with different biological agents and 69 healthy controls, we genotyped IL-17A rs2275913 and IL-17F rs763780 variants using TaqMan probes.
UNASSIGNED: We did not observe statistically significant changes in genotype frequencies of IL-17A rs2275913 (p = 0.922) and IL-17F rs763780 (p = 0.621) variants between patient and control groups. Although we did not find any association between these polymorphisms and the development of psoriasis, statistical analyses showed that individuals with the IL-17A AA genotype had shorter disease duration (9.09 ±6.82, p = 0.020) and AA genotype frequency was higher in patients who used single conventional treatment (34.6%; p = 0.025). IL17A/rs2275913 variant in terms of disease duration, it was observed that individuals with AA genotype had a shorter disease duration (less than 10 years) (p = 0.009). For patients with PASI90 and PASI100 response, the IL-17A AA genotype was significantly higher (p = 0.015). On the other hand, we did not detect any statistically significant correlation between variants and response to biological agents.
UNASSIGNED: According to our results, we may suggest that rs2275913 variant seems to be associated with disease duration, use of single conventional treatment and responsiveness of PASI90 and PASI100 however both variants have no effect on the susceptibility to psoriasis in the population of Eastern Turkey.
摘要：
■IL-17A和IL-17F细胞因子在银屑病的发病机制中具有重要作用。
■研究IL-17Ars2275913和IL-17Frs763780变体与银屑病发展的关联，以及这些多态性是否影响生物制剂的反应性。
■在我们的病例对照研究中，其中包括83名接受不同生物制剂治疗的银屑病患者和69名健康对照，我们使用TaqMan探针对IL-17Ars2275913和IL-17Frs763780变体进行基因分型。
■我们没有观察到患者组和对照组之间IL-17Ars2275913（p=0.922）和IL-17Frs763780（p=0.621）变体的基因型频率有统计学上的显着变化。虽然我们没有发现这些多态性与银屑病的发展之间的任何关联，统计分析表明,IL-17AAA基因型患者的病程较短(9.09±6.82,p=0.020),而使用单一常规治疗的患者中AA基因型频率较高(34.6%;p=0.025).IL17A/rs2275913在疾病持续时间方面的变异，观察到AA基因型个体的病程较短(小于10年)(p=0.009).对于有PASI90和PASI100反应的患者，IL-17AAA基因型显著较高(p=0.015)。另一方面,我们没有检测到变异体和对生物制剂的应答之间有统计学意义的相关性.
■根据我们的结果，我们可能认为rs2275913变异似乎与疾病持续时间有关，使用单一常规治疗和PASI90和PASI100的反应性，但是这两种变体对土耳其东部人群的银屑病易感性没有影响。
■研究IL-17Ars2275913和IL-17Frs763780变体与银屑病发展的关联，以及这些多态性是否影响生物制剂的反应性。
■在我们的病例对照研究中，其中包括83名接受不同生物制剂治疗的银屑病患者和69名健康对照，我们使用TaqMan探针对IL-17Ars2275913和IL-17Frs763780变体进行基因分型。
■我们没有观察到患者组和对照组之间IL-17Ars2275913（p=0.922）和IL-17Frs763780（p=0.621）变体的基因型频率有统计学上的显着变化。虽然我们没有发现这些多态性与银屑病的发展之间的任何关联，统计分析表明,IL-17AAA基因型患者的病程较短(9.09±6.82,p=0.020),而使用单一常规治疗的患者中AA基因型频率较高(34.6%;p=0.025).IL17A/rs2275913在疾病持续时间方面的变异，观察到AA基因型个体的病程较短(小于10年)(p=0.009).对于有PASI90和PASI100反应的患者，IL-17AAA基因型显著较高(p=0.015)。另一方面,我们没有检测到变异体和对生物制剂的应答之间有统计学意义的相关性.
■根据我们的结果，我们可能认为rs2275913变异似乎与疾病持续时间有关，使用单一常规治疗和PASI90和PASI100的反应性，但是这两种变体对土耳其东部人群的银屑病易感性没有影响。
